Gilead Sciences CEO's pay climbed to $23.7 million
Gilead Sciences Inc. CEO Daniel O'Day's compensation rose 4.8% last year to $23.7 million — roughly $97 for every buck made ...
Fierce Pharma3d
Another big payday for O'Day as Gilead boosts his compensation 5% to $23.7M
Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the steadily upward trajectory of the company since ...
Gilead’s HIV Treatments Could Face Headwinds. Why the Stock Will Still Rise.
Gilead Sciences stock has room to climb, and investors shouldn’t overlook the company’s impressive record in navigating HIV policy, Citi Research says. Analysts led by Geoff Meacham reiterated a Buy ...
Stocktwits on MSN11d
Gilead Stock Wobbles On Federal HIV Funding Cut Buzz, But Retail And Analysts Stay Unfazed
Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...
Fierce Pharma5d
Potential federal budget cuts won't rock Gilead's HIV boat too much: analysts
News of potential federal budget cuts impacting HIV drugs in the U.S. was quickly reflected in a dip in share prices for top ...
A Closer Look at Gilead Sciences's Options Market Dynamics
Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.
Explore more
Stock of the Day: Gilead Sciences falls on report the Trump administration could slash funds for HIV prevention
The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.
3GILD : What Analysts Are Saying About Gilead Sciences Stock
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...